A systematic review of biologics for the treatment of noninfectious uveitis

• Published in: Immunotherapy Vol. 5; no. 1; pp. 91 - 102
• Main Author: Takeuchi, Masaru
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.01.2013
• Subjects: Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Autoimmune diseases; biologic agent; Biological Products - immunology; Biological Products - therapeutic use; biologics; Care and treatment; Cell adhesion & migration; Clinical trials; Corticoids; Disease; Drug dosages; Drug therapy; Free radicals; Health aspects; Humans; immune therapy; Immunosuppressive agents; Immunotherapy; Immunotherapy - methods; monoclonal antibody; Pathogenesis; Patients; Randomized Controlled Trials as Topic; Remission; Reviews; Risk factors; Therapeutic applications; TNF inhibitors; treatment; Treatment Outcome; Uveitis; Uveitis - immunology; Uveitis - therapy; Japan
• ISSN: 1750-743X; 1750-7448
• DOI: 10.2217/imt.12.134

Noninfectious uveitis is a potentially sight-threatening ocular disorder and variable therapeutic strategies have been proposed. Biologic therapies were introduced as a new option for patients with uveitis refractory to the conventional therapy using corticosteroids and immunosuppressive agents, and 10 years have passed since the initiation. In this review, the author summarizes current articles on the assessment of therapeutic application of biologics for refractory uveitis including other autoimmune diseases. Although some results are based on investigation with insufficient clinical trials, especially in biologics, the majority of biologics indicate preferable outcomes on refractory uveitis, with remarkable promise to increase the possibility of long-term remissions.